Rapport de veille

Celosia Therapeutics wins top $2m grant as NSW funds six startups

An MND gene therapy developer took the largest award as six NSW startups split $7 million from a new state commercialisation fund.

INSIGHTEX Editorial Desk

2 min de lecture

Celosia Therapeutics wins top $2m grant as NSW funds six startupsRapport de veille

What happened

Celosia Therapeutics, a biotech working on motor neurone disease, has secured $2 million, the largest grant on offer, from a new NSW government fund for commercialising emerging technology, Startup Daily reported. Six startups split $7 million in the round, which drew applications from more than 250 businesses. Celosia was the only one awarded the maximum amount.

Chief executive Dr Kathryn Sunn said the money would help the company broaden its MND pipeline. It will fund candidate development, manufacturing and preclinical studies while its lead program, CTx1000, is studied in patients with sporadic ALS. Over two years, Celosia will work with the NSW Viral Vector Manufacturing Facility to make a second gene therapy at larger scale and test its quality before future clinical studies.

The other grants went to Agscent, Hullbot, Syenta, Deteqt and Zetifi. Agscent, awarded $1.25 million, plans to take its cattle breath test for respiratory disease into commercial feedlots. Hullbot is building a ship-mounted dock for its hull-cleaning robot. Deteqt is preparing to make a tiny quantum magnetometer. Syenta is developing finer chip connections. Zetifi is building ZetiSky, an antenna that switches between mobile towers and satellites.

Context

The $20 million fund runs for three years under the NSW Innovation Blueprint 2035, and its next round opens in 2027. Celosia grew out of Macquarie University research by Lars Ittner and Yazi Ke into TDP-43, a protein that forms toxic clumps in nerve cells in about 97% of ALS cases. The company raised a $16.75 million Series A led by Uniseed in 2024 and dosed its first phase 1b trial participant with CTx1000 in March.

SourceStartup Daily

Le briefing

La semaine tech, en un seul e-mail.

Les dépêches qui méritent votre temps, chaque semaine. Désinscription à tout moment.